These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 9627740)

  • 61. Tardive dyskinesia, lipid peroxidation, and sustained amelioration with vitamin E treatment.
    Peet M; Laugharne J; Rangarajan N; Reynolds GP
    Int Clin Psychopharmacol; 1993; 8(3):151-3. PubMed ID: 8263312
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Vitamin E in tardive dyskinesia.
    Schneiderhan ME
    Ann Pharmacother; 1993 Mar; 27(3):311-3. PubMed ID: 8453169
    [No Abstract]   [Full Text] [Related]  

  • 63. Randomised double-blind comparison of the incidence of tardive dyskinesia in patients with schizophrenia during long-term treatment with olanzapine or haloperidol.
    Beasley CM; Dellva MA; Tamura RN; Morgenstern H; Glazer WM; Ferguson K; Tollefson GD
    Br J Psychiatry; 1999 Jan; 174():23-30. PubMed ID: 10211147
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Benzodiazepines for neuroleptic-induced tardive dyskinesia.
    Bhoopathi PS; Soares-Weiser K
    Cochrane Database Syst Rev; 2006 Jul; (3):CD000205. PubMed ID: 16855954
    [TBL] [Abstract][Full Text] [Related]  

  • 65. The use of clonidine in the treatment of neuroleptic-induced tardive dyskinesia.
    Browne J; Silver H; Martin R; Hart R; Mergener M; Williams P
    J Clin Psychopharmacol; 1986 Apr; 6(2):88-92. PubMed ID: 2871058
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Withdrawal-emergent dyskinesia in patients with schizophrenia during antipsychotic discontinuation.
    Schultz SK; Miller DD; Arndt S; Ziebell S; Gupta S; Andreasen NC
    Biol Psychiatry; 1995 Dec; 38(11):713-9. PubMed ID: 8580223
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Vitamin E in the treatment of tardive dyskinesia: a preliminary study over 7 months at different doses.
    Sajjad SH
    Int Clin Psychopharmacol; 1998 Jul; 13(4):147-55. PubMed ID: 9727725
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Efficacy and safety of different pharmacological interventions in the treatment of tardive dyskinesia: a systematic review and network meta-analysis.
    Ismail O; Albdour K; Jaber Y; Jaber K; Alsaras A
    Eur J Clin Pharmacol; 2024 Oct; 80(10):1471-1482. PubMed ID: 38969949
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Schizophrenia Synaptic Pathology and Antipsychotic Treatment in the Framework of Oxidative and Mitochondrial Dysfunction: Translational Highlights for the Clinics and Treatment.
    De Simone G; Mazza B; Vellucci L; Barone A; Ciccarelli M; de Bartolomeis A
    Antioxidants (Basel); 2023 Apr; 12(4):. PubMed ID: 37107350
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Recent Reports on Redox Stress-Induced Mitochondrial DNA Variations, Neuroglial Interactions, and NMDA Receptor System in Pathophysiology of Schizophrenia.
    Beeraka NM; Avila-Rodriguez MF; Aliev G
    Mol Neurobiol; 2022 Apr; 59(4):2472-2496. PubMed ID: 35083660
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Vitamin E for antipsychotic-induced tardive dyskinesia.
    Soares-Weiser K; Maayan N; Bergman H
    Cochrane Database Syst Rev; 2018 Jan; 1(1):CD000209. PubMed ID: 29341067
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Antioxidant treatments for schizophrenia.
    Magalhães PV; Dean O; Andreazza AC; Berk M; Kapczinski F
    Cochrane Database Syst Rev; 2016 Feb; 2(2):CD008919. PubMed ID: 26848926
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Pyridoxal 5 phosphate for neuroleptic-induced tardive dyskinesia.
    Adelufosi AO; Abayomi O; Ojo TM
    Cochrane Database Syst Rev; 2015 Apr; 2015(4):CD010501. PubMed ID: 25866243
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Motor symptoms of schizophrenia: is tardive dyskinesia a symptom or side effect? A modern treatment.
    Lerner V; Miodownik C
    Curr Psychiatry Rep; 2011 Aug; 13(4):295-304. PubMed ID: 21519907
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Effect of alpha lipoic acid on the tardive dyskinesia and oxidative stress induced by haloperidol in rats.
    Thaakur S; Himabindhu G
    J Neural Transm (Vienna); 2009 Jul; 116(7):807-14. PubMed ID: 19444377
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Effect of chronic N-acetyl cysteine administration on oxidative status in the presence and absence of induced oxidative stress in rat striatum.
    Harvey BH; Joubert C; du Preez JL; Berk M
    Neurochem Res; 2008 Mar; 33(3):508-17. PubMed ID: 17763945
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Effect of spirulina maxima on the haloperidol induced tardive dyskinesia and oxidative stress in rats.
    Thaakur SR; Jyothi B
    J Neural Transm (Vienna); 2007 Sep; 114(9):1217-25. PubMed ID: 17530160
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Extrapyramidal symptoms with atypical antipsychotics : incidence, prevention and management.
    Pierre JM
    Drug Saf; 2005; 28(3):191-208. PubMed ID: 15733025
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Tocopherol (vitamin E) in Alzheimer's disease and other neurodegenerative disorders.
    Berman K; Brodaty H
    CNS Drugs; 2004; 18(12):807-25. PubMed ID: 15377170
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Behavioral and antioxidant activity of a tosylbenz[g]indolamine derivative. A proposed better profile for a potential antipsychotic agent.
    Zika CA; Nicolaou I; Gavalas A; Rekatas GV; Tani E; Demopoulos VJ
    Ann Gen Hosp Psychiatry; 2004 Jan; 3(1):1. PubMed ID: 14711381
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.